Redmile Group, LLC Stoke Therapeutics, Inc. Transaction History
Redmile Group, LLC
- $908 Million
- Q3 2025
A detailed history of Redmile Group, LLC transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Redmile Group, LLC holds 4,175,542 shares of STOK stock, worth $111 Million. This represents 10.81% of its overall portfolio holdings.
Number of Shares
4,175,542
Previous 4,375,931
4.58%
Holding current value
$111 Million
Previous $49.7 Million
97.57%
% of portfolio
10.81%
Previous 6.04%
Shares
25 transactions
Others Institutions Holding STOK
# of Institutions
160Shares Held
60.2MCall Options Held
563KPut Options Held
101K-
Black Rock Inc. New York, NY5.41MShares$143 Million0.0% of portfolio
-
Lynx1 Capital Management LP San Juan, PR5.4MShares$143 Million24.66% of portfolio
-
Rtw Investments, LP New York, NY5.12MShares$136 Million1.61% of portfolio
-
Baker Bros. Advisors LP New York, NY4.63MShares$123 Million0.89% of portfolio
-
Morgan Stanley New York, NY3.54MShares$93.8 Million0.01% of portfolio
About Stoke Therapeutics, Inc.
- Ticker STOK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,419,300
- Market Cap $1.05B
- Description
- Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...